DUBLIN--(BUSINESS WIRE)--The "Polycythemia Vera - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Polycythemia Vera - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 3 and 2 respectively.
Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Polycythemia Vera - Overview
- Polycythemia Vera - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Polycythemia Vera - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Polycythemia Vera - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Galena Biopharma Inc
- Gilead Sciences Inc
- Italfarmaco SpA
- Nerviano Medical Sciences Srl
- PharmaEssentia Corp
For more information about this report visit https://www.researchandmarkets.com/research/h7wqnv/polycythemia_vera
